Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease : a systematic review of clinical benefit. / Ulrik, Charlotte Suppli.
In: International Journal of Chronic Obstructive Pulmonary Disease, Vol. 7, 2012, p. 673-8.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease
T2 - a systematic review of clinical benefit
AU - Ulrik, Charlotte Suppli
PY - 2012
Y1 - 2012
N2 - Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.
AB - Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD.
U2 - 10.2147/COPD.S35990
DO - 10.2147/COPD.S35990
M3 - Journal article
C2 - 23055716
VL - 7
SP - 673
EP - 678
JO - International Journal of COPD
JF - International Journal of COPD
SN - 1176-9106
ER -
ID: 48598189